A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first‐line therapy for patients with breast cancer (<scp>CBCRT</scp>01)Jianghao Chen, Ling Wang, Xiaodong Zhou et al.|International Journal of Cancer|2017Cited by 30